- Recent safety and efficacy data in both Ulcerative Colitis and Pouchitis continue to support MH002’s potential in indications characterized by mucosal damage and inflammation.
GHENT, Belgium -- (...
Group Affirms Full-year Outlook
MUNICH -- (BUSINESS WIRE) --
May 15, 2024
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2024051405048...
OSAKA, Japan & CAMBRIDGE, Mass. -- (BUSINESS WIRE) --
Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meetin...